Eden Research Share Discussion Threads

[astralvision] 12/12/2017 09:57

AttyGYou make some fair points but wrt to Michael Walters his first report once the Eastman deal was signed, dated 21/12/16 gave 2019 as the first year of sales.Other than that I agree with your points, Eden could have given so much more detail, with what has been issued you wonder why they bothered. The share price reaction confirms the same.

[attyg] 12/12/2017 09:45

Annual milestones are due from Eastman, why didn't they refer to the payment?
If not paid, why couldn't they have said the amount due - we will be able to see it in the segmental reporting.

Oh well, I guess we'll see the share options awarded to directors in the AR as well as the annual milestones.

Hey ho.

[attyg] 12/12/2017 09:03

Redhill: I can't see it on the Eden website - perhaps my browser is not refreshing the pages? Where is it?

Ah, I see it now under INVESTORS, Regulatory News; whereas I thought it might either be on the Home page and certainly where I (clearly wrongly) go to - MEDIA - Latest News.
Of course having signed up to have all communications emailed to my email account doesn't help - they don't get sent out, well not to me.

Investingisatrickygame:

In last December's RNS, Eden wrote:

Nematodes are a major category of plant pest that cause an estimated $300 million of damage per year in Europe alone. Most major crops are affected by nematodes with particular damage being done in the high value fruit and vegetables segment. This segment of the nematicide market is in the region of $550m globally.

This example of wording continues to make Eden opaque.
$300m of damage and then a market of $550m.
Apples and Pears.


The Eden story is such a good one, yet time and again the Eden communications leave one wondering just what the size is of the total market, what is Eden's target market within the total, what does it reasonably expect to achieve as a market share, and of that market value - what does Eden get royalties on - the end user price, or the wholesale price, which is likely to be half of the end user market value. Then over what time frame.
While 3AEY is now manufactured by toll manufacturers on behalf of Eden and then Eden sells to Sipcam etc, my understanding is that Cedroz will not be manufactured by Eden - so what does this announcement mean to Eden £ wise?
Well I can't work it out because Eden does not provide any indications or information from which anyone might be able to determine the possible impact.

Mind you, having written in the AR in May that:

"Eastman are aiming to launch CedrozTM commercially in 2019 or sooner, where allowed. "

then to write only 6 months later

"The first sales are expected towards the end of 2019."

what do we expect in the way of clarity from the Board.

Come on Eden - why don't you give some thought to making the company more transparent and then you might find PIs stop selling and someone starts buying.

[investingisatrickygame] 12/12/2017 08:23

Possibly Europe is, but let's not forget that they also said "This segment of the nematicide market is in the region of $550m globally" so the overall market is +83% on top of the EU.

So likely chasing the biggest market first.

[redhill9] 12/12/2017 08:20

Atty, good post. The RNS is on the Eden website, that's where I saw it.

[attyg] 12/12/2017 08:04

I am surprised that this has been put out.
Is it meant to stop the slide in the sp?

With Eastman being an important US company, I was expecting them to be pressing ahead with and obtaining approvals in the various states of america. I was also expecting USA to be a bigger market than Israel, Europe and Mexico - maybe that is not the case. Do we assume Europe is the EU, part of the EU or the whole of what is called Europe?

Sadly little clarity there - doubtless intended.

From last year's RNS "Nematodes are a major category of plant pest that cause an estimated $300 million of damage per year in Europe alone." So perhaps "Europe" is the biggest market.

I recall MW initially wrote that sales might possibly occur late 2018 - he must have been advised that was a hope, at least, by Eden, who wrote in last year's AR

"Eastman are aiming to launch CedrozTM commercially in 2019 or sooner, where allowed. "


Now we read that "The first sales are expected towards the end of 2019."

Oh well.

The major positive is that Eastman are indeed moving ahead with Cedroz.

Perhaps its time for Eden to move ahead and place their RNS on their website?

[redhill9] 12/12/2017 07:56

Another step along the path. The final paragraph is important reading for those who doubt Eden's potential - Eastman don't mess around.

[attyg] 12/12/2017 07:49

12 December 2017

Eden Research plc

("Eden" or "Company)


Regulatory progress update


Eden Research plc (AIM: EDEN), the AIM listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that its distribution partner, Eastman Chemical ("Eastman"), has announced the submission of the regulatory dossiers for its new nematicide, CedrozTM. Cedroz will be a new tool for farmers to control a wide range of economically important nematodes.

The first product dossiers were submitted to the authorities in Israel, Europe, and Mexico for the use in fruit and vegetable farming against root knot nematodes. The first sales are expected towards the end of 2019.

Cedroz is an innovative formulation based on specific nature-identical terpenes and based on an encapsulation technology which was developed and patented by Eden Research plc ("Eden"). Eastman is Eden's exclusive partner for the development and distribution of this product in more than 25 key countries around the world. The favourable toxicological regulatory profile of Cedroz will provide a high level of flexibility on the timing of application for farmers and comfort for the workers. In all regulatory trials completed, no residues were found in the crops at harvest.

Sean Smith, Chief Executive Officer of Eden, said: "We are very pleased with the progress that Eastman has made with the far-reaching registration of Cedroz in their territories. They have proven themselves to be a dedicated and efficient partner, and in tackling such a large undertaking, they are building an impressive platform for the commercialization of Cedroz as an important solution to the challenges that nematodes create for farmers globally".

Guy Van Den Bossche, General Manager of Eastman's Crop Protection business, said: "Eastman is a leading supplier in soil disinfection for high value crops, and extending our portfolio worldwide with this new post-planting nematicide is an exciting step for our customers. The sustainable profile and the agronomical performance of Cedroz offers a solution to the challenges in the soil treatment market and broader societal need for increasing sustainability in crop protection."

[supersonico] 11/12/2017 18:51

The bio is a priori paré many virtues. But is it really better for health? European researchers have addressed this thorny issue, which increasingly divides the scientific community as organic farming gains ground around the world.
In the largest literature review on the subject, published Friday, October 27 in Environmental Health, they identify a series of beneficial effects on human health related to the production and consumption of food without any synthetic fertilizer or phytosanitary products chemical. Above all, they observe a wide range of disorders caused by pesticide residues, starting with adverse consequences on the cognitive development of the child.
Everywhere on the planet, the bio is progressing. It concerned 51 million hectares cultivated in 179 countries at the end of 2015, mainly in Australia and Europe. On the Old Continent, this area reached 11 million hectares in the same year, or 6.2% of arable land (compared to 3.6% ten years ago). In France finally, these figures amounted to 1.8 million hectares on June 30 (+ 15% in six months), and 6.5% of the useful agricultural area, according to the latest data from Agence Bio.
Despite this undeniable boom, research on the health effects of this mode of cultivation is still scarce. "Most of the work on consumption impacts does not differentiate between conventional and organic agriculture. We also face a heterogeneity of data, "says Emmanuelle Kesse-Guyot, one of the authors of the study, epidemiologist and research director at the National Institute of Agricultural Research (INRA) in the research team in nutritional epidemiology (Inserm / INRA / CNAM / University Paris-XIII), the only unit to work on this topic in France.

...................................

[supersonico] 11/12/2017 17:51

Watch this..

[supersonico] 11/12/2017 15:29

THE THORN
by William Wordsworth
I.

There is a thorn; it looks so old,
In truth you'd find it hard to say,
How it could ever have been young,
It looks so old and grey.
Not higher than a two years' child
It stands erect this aged thorn;
No leaves it has, no thorny points;
It is a mass of knotted joints,
A wretched thing forlorn.
It stands erect, and like a stone
With lichens it is overgrown.

[supersonico] 11/12/2017 13:29

Lykele van der Broek

[supersonico] 11/12/2017 13:29

Lykele van der

[supersonico] 11/12/2017 13:06

Lykele van

[supersonico] 11/12/2017 12:45

Lykele van der Broek seems to think it will and he's one of the smartest fellas in the industry.

[investingisatrickygame] 11/12/2017 12:44

supersonico, I think you've covered it :)

[littlealbatross2] 11/12/2017 12:35

So much potential....will it ever be realised?

[supersonico] 10/12/2017 20:19

Eden Gets Growing - (EDEN)
29/9/2017 (119264)

Eden Gets Growing

As ever, investing in Eden Research (EDEN) requires patience. Interim results for the first half of 2016 disappointed the market, and the shares slipped, closing at 11p to 11.75p in a little flurry of selling after rising to 13p.

Perhaps an updated note from house broker Shore Capital did the damage. Headlined ‘A vote of confidence’ and taking encouragement from the £2.2m investment in a 9.9% stake by Sipcam, the note repeated earlier predictions of revenues for 2016 at £1.7m with pre-tax losses of £1.5m, and went on to suggest there would still be a small loss by 2020, though revenues could have risen to £5.7m by then.

While these figures are estimated on a conservative basis, using only contracted deals, they must bring a weary sigh from investors who have believed that Eden’s all natural terpene technology, combined with the slow-release encapsulation method, will eventually command a worthwhile share of the agrochemical and several related markets.

An updated presentation from Eden at helps give a glimpse of the opportunities. Page eight lists Eden’s target markets and their size by 2020 – biopesticides (worth $6.9bn with Eden products to tackle botrytis, powdery and downy mildew, slug and snail treatment and mites and white flies); conventional pesticides ($76.8bn and Eden in co-encapsulated conventional synthetic pesticides and formulation delivery systems); and animal health ($33bn with Eden in companion animal flea and tick products, odour control, and ear, coat and skin care).

Eden simply has to scratch the surface of this stuff to suggest the current £23m market capitalisation is too modest. That explains why many subscribers have been ready to sit and wait while Eden moves towards becoming a real company. It has the patents (over 122 granted and pending), and is starting to hack a way through the regulatory forest, and picking up major name partners to finance and market product along the way. But, by golly, it takes time.

The half-year figures show that, at last, the possibilities are starting to translate into real sales. Revenue was up by £900,000 to just over £1m. Half of that came when Sipcam agreed an option and evaluation deal which would allow it first option on Eden ‘s plant protection products in certain markets. But revenues from 3AEY, Eden’s initial product for tackling botrytis in grapes, must have risen by some £400,000. Part of this was because of a switch which saw Eden producing and selling 3AEY instead of taking a royalty.

Unusual weather conditions – frost, then excessive heat and drought – have impacted sales through the summer, and while 3AEY has been very well received, it is impossible to predict second half sales firmly. Eden, though, accepts that the Shore annual revenue target of £1.7m makes sense.

Looking ahead, regulatory approval for 3AEY in France came late in the season, and Portugal has only just come through. All of the key European grape-growing countries are now in the fold, and there is a steady flow of label extensions, approving use on additional crops.

So there is a growing run of repeatable revenue from sales. And Sipcam option cash – perhaps a larger amount than this year - ought to chip in again in 2018 as Sipcam evaluates and picks up options to sell 3AEY in other areas. It is a global operator with sales approaching £1bn, and is linked to Japanese giant Sumitomo.

Crucially, the Sipcam partnership has eased financial pressures. At the half-year, Eden had cash of £3.66m. That is allowing it to take on more personnel, pursue more regulatory clearances, and generally advance the business. Shore Capital projects that £3.1m cash will remain at the end of the year. There are current trials on five continents, and registration applications are pending in 29 countries.

There could be significant new deals before the end of the year. Meanwhile work continues with US giant Eastman, and a nematicide is on track for launch in 29 countries. The long-awaited and oft-postponed launch of by Bayer of animal health products in the USA is expected in the first quarter of 2018. Even TerpeneTech might launch a head lice product early next year.

None of these new products and markets is built into the cautious broker forecasts, and could generate significant payments and then royalties. So the forecast figures almost certainly understate the potential value of Eden, and the labour and direct expense of pushing through regulatory approvals for Eden’s three key terpenes.
The broker takes a positive view of Eden, saying ‘We continue to believe Eden is well-placed with a growing and diverse product development pipeline in an industry that is seeing structural growth in demand for natural solutions. This is in the context of it getting harder to get product registrations for synthetic conventional pesticides which is a market with an overall value of over $57bn per year. So with higher barriers to entry we believe Eden can drive value creation going forward.’

A new chairman steps in on January 1. Hopefully he will have the experience and contacts to help drive Eden forward. He ought certainly to add credibility. Lykele van der Broek was former chief operating officer of Bayer Crop Science and former head of the animal health care division of Bayer Health Care. He is 60, and while he is aware of it, is not involved in the Eden animal health deal with Bayer. His arrival ought to be encouraging – at Bayer he would have had experience of running the biggest crop protection company in the world.

It all helps add to the possibilities in Eden. It is taking a long, long time to realise the potential of terpenes and encapsulation, but the agro-industry is governed by the seasons, and though it is tempting to think otherwise, big companies do not readily beat a path to small players with bright ideas. It is slog, slog, slog, especially given the heavy regulatory framework governing such areas (though it is hard to forgive the glacial pace at which this often moves).

Eden is staring to deliver product in the real world, but the attraction remains the potential. The vast scope for all-natural pesticides is increasingly recognised, but Eden’s terpenes might do so much more. Even now, with 3AEY for botrytis selling well in the early stages, there are many related applications yet to be exploited and vast areas of the world where no-one has yet picked up the distribution rights.

The theme will be familiar to subscribers Not this year, maybe next year, but give it time and Eden could be a big winner. Who knows? One of the giants might come to understand that, too.

I have a holding in Eden Research.

Ends

[supersonico] 10/12/2017 19:49

Increasing food security issues across the globe due to population outburst is further supporting the demand for bio pesticides in developing as well as developed nations. Major agrarian economies such as India, Brazil, etc., are extensively adopting sustainable crop protection products and pesticides in their farming methods, which is anticipated to drive the global bio pesticides market over the coming years.
The global bio pesticides market is projected to grow at a CAGR of more than 16% by 2026. The growth in the global bio pesticides market is expected on account of various promotional activities carried out by government agencies and groups to replace the hazardous and expensive synthetic pesticides with environment-friendly and inexpensive substitutes.

[supersonico] 10/12/2017 19:31

“There’s no reason food companies should look overseas when the best farmers in the world are right here in Pennsylvania,” Casey said in a news release. “As demand for organic products grows, we must do all we can to help American farmers and ranchers meet this demand.

[supersonico] 09/12/2017 00:35

Date: Nov 22, 2017
Location: Merelbeke, BE
Global Marketing Director, Crop Protection
Ghent, Belgium

Do you possess strong strategic and thought leadership capabilities combined with deep knowledge of the Crop Protection industry? Welcome to Eastman Chemical Company…

This is Eastman Chemical Company
Eastman is a global specialty chemical company that produces a broad range of products found in items people use every day. With a portfolio of specialty businesses, Eastman works with customers to deliver innovative products and solutions while maintaining a commitment to safety and sustainability. Our market-driven approaches take advantage of world-class technology platforms and leading positions in attractive end-markets such as transportation, building and construction, and consumables. Eastman focuses on creating consistent, superior value for all stakeholders. As a globally diverse company, Eastman serves customers in approximately 100 countries and had 2016 revenues of approximately $9 billion. The company is headquartered in Kingsport, Tennessee, USA and employs approximately 15,000 people around the world.

This is the role
The Global Marketing Director is responsible for developing the marketing strategy for Crop Protection. You share responsibly with other directors and marketing managers to ensure in-depth marketing tools and techniques are developed and applied to all growth projects. You are a strategic stakeholder for the business organization and innovation platforms. You ensure optimal insights in end-markets and applications are included when developing business strategies, scoping growth initiatives, and leading market facing growth projects.